This study is testing a new drug called AVA6103 in people with certain advanced solid tumors, including vulvar, pancreatic, stomach, GEJ (where the esophagus meets the stomach), and cervical cancers. AVA6103 is designed to be activated by a protein called FAP, which is often found in these types of tumors. The main goals are to see how safe AVA6103 is, what side effects it causes, and to find the best dose. This is a "first-in-human" study, meaning it's one of the first times this drug is being given to people. You might be able to join if you have one of these cancers that is locally advanced (cannot be removed by surgery) or has spread, and your tumor is believed to be FAP positive.

Study design

This is an open-label, multi-center Phase 1 study, meaning both you and your doctors will know you are receiving AVA6103. It plans to enroll 174 participants and has two parts: a dose escalation phase to find the right dose, and a dose expansion phase to further test that dose.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from the first day of treatment until up to 30 days after your last dose of AVA6103.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.